Related Experiment Video
Updated: Jul 8, 2026
07:38
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
[New perspectives for bradykinin in nephroprotection]
Marie Buléon1, Marion Mehrenberger, Christiane Pécher
1Inserm, U858/I2MR, Remodelage rénal et cardiaque, 1, avenue Jean Poulhes, BP 84225, 31432 Toulouse Cedex 4, France.
Medecine Sciences : M/S
|December 25, 2007
Summary
The bradykinin B2 receptor plays a key role in protecting kidneys from diseases like diabetes and hypertension. Targeting this receptor may offer new treatments for kidney damage.
Area of Science:
- Nephrology
- Pharmacology
- Molecular Biology
Context:
- Arterial hypertension, diabetes, and obesity frequently lead to irreversible renal diseases.
- Current therapies, including glycemic control and renin-angiotensin system blockade, have limitations in preventing end-stage renal failure.
Purpose:
- To investigate the role of the bradykinin B2 receptor in the nephroprotective effects of renin-angiotensin system inhibitors.
- To explore the potential of bradykinin B2 receptor agonists as a novel therapeutic strategy for nephropathies.
Summary:
- Evidence suggests the bradykinin B2 receptor mediates nephroprotective effects previously attributed solely to angiotensin II blockade.
- Studies in B2 receptor knockout mice show exacerbated glomerulosclerosis, highlighting the receptor's protective role.
- The B2 receptor may reduce proteinuria, fibrosis, cell proliferation, and oxidative stress in the kidneys.
Impact:
- Bradykinin B2 receptor agonists represent a promising new therapeutic target for managing kidney diseases associated with diabetes and vascular conditions.
- Understanding the B2 receptor's role could lead to more effective treatments for diabetic nephropathy and other kidney disorders.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...